Titan Securities Limited has filed its mandatory report with BSE Limited regarding transfer requests processed under SEBI's special window during the first week of January 2026. The report, submitted on February 17, 2026, covers the period from January 1 to January 6, 2026, as required under SEBI Circular SEBI/HO/MIRSDPoD/P/CIR/2025/97 dated July 2, 2025.

Transfer Request Activity Summary

The company's transfer activity during the specified period showed minimal volume, with only one request received for processing. The detailed breakdown of transfer requests is presented below:

Regulatory Compliance Framework

The report submission aligns with SEBI's regulatory requirements for listed companies to maintain transparency in share transfer operations. The special window mechanism allows shareholders to re-lodge physical share transfer requests that may have been previously rejected or remained unprocessed.

Registrar and Transfer Agent Confirmation

BEETAL Financial & Computer Services Pvt Ltd, serving as the company's Registrar and Transfer Agent, provided confirmation of the transfer statistics. The RTA, which holds SEBI registration number INR 000000262 as a Category I Registrar & Share Transfer Agent, prepared and validated the transfer data for the reporting period.

Corporate Communication Details

The report was signed by Akansha Sharma, Company Secretary and Compliance Officer of Titan Securities Limited, and submitted to BSE Limited's Corporate Services Department. The company trades on BSE under scrip code 530045, and maintains its registered office at Lusa Tower, Azadpur Commercial Complex, Delhi.

The 18-day processing time for the single transfer request indicates the company's adherence to prescribed timelines for evaluating and responding to shareholder transfer applications under the special window provisions.

Titan Securities Limited announced its unaudited financial results for the third quarter ended December 31, 2025, showing mixed performance across standalone and consolidated operations. The Board of Directors approved these results at their meeting held on February 12, 2026.

Standalone Financial Performance

The company's standalone operations faced challenges during Q3FY26, with net profit declining significantly compared to the previous year. Revenue from operations also contracted substantially during the quarter.

The revenue decline was primarily attributed to lower sales of products (shares) which dropped to ₹44.85 lakhs from ₹273.81 lakhs in the corresponding quarter of the previous year. Dividend income remained relatively stable at ₹56.25 lakhs compared to ₹57.51 lakhs in Q3FY25.

Nine-Month Performance Analysis

For the nine-month period ended December 31, 2025, standalone performance showed continued pressure with total revenue from operations at ₹315.47 lakhs versus ₹778.97 lakhs in the corresponding period of FY25. Net profit for the nine-month period was ₹42.82 lakhs compared to ₹124.13 lakhs in the previous year, representing a decline of 65.51%.

Consolidated Results Show Strength

Despite standalone challenges, the consolidated results presented a robust picture, primarily driven by strong contributions from associate companies.

The consolidated results include contributions from associate companies Titan Biotech Limited and Peptech Biosciences Limited, which contributed ₹329.30 lakhs to the overall profit during Q3FY26.

Key Financial Highlights

The company maintained a stable capital structure with paid-up equity share capital remaining constant at ₹2,501.62 lakhs across all reporting periods. Other comprehensive income for the standalone entity was ₹27.91 lakhs in Q3FY26, primarily driven by re-measurement of equity instruments through other comprehensive income worth ₹36.54 lakhs.

Regulatory Compliance and Auditor Review

The financial results were reviewed by the Audit Committee and approved by the Board of Directors. The results have been subject to limited review by the statutory auditors Goyal Nagpal & Co., Chartered Accountants, in accordance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has elected to exercise the option under section 115BAA of the Income Tax Act, 1961, for tax calculations.